Citations

Clear

431 citation(s) found for "Schmidt, B".

Abstract WP204: Genetic Variant in VCAM1 Mediates Acute Infarct Size in Ischemic Stroke Patients
Xu, Huichun , McArdle, Patrick F. , Jiménez‐Conde, Jordi , Kleindorfer, Dawn , Schmidt, Reinhold, Sharma, Pankaj , Słowik, Agnieszka , Woo, Daniel , Worrall, Bradford B. , Golland, Polina , Kittner, Steven J. , Rost, Natalia S. , Giese, Anne‐Katrin , Musolino, Patricia L. , Ryan, Kathleen A. , Schirmer, Markus D. , Dalca, Adrian Vasile , Cole, John W. , Broderick, Joseph P. , Jern, Christina , Kissela, Brett , Lemmens, Robin , Lindgren, Arne G. , Meschia, James F. , Rundek, Tatjana , Sacco, Ralph L. , Thijs, Vincent , Rosand, Jonathan M. , Mitchell, Braxton D. , Wu, Ona

Mayo Clinic

Stroke | June 21, 2021 | Volume: 48 | Issue: suppl_1 | Pages: No page available

10.1161/str.48.suppl_1.wp204 Get It

Introduction: Even though neuroinflammation is increasingly recognized as an essential contributor to ischemic brain injury, the exact underlying mechanisms remain unclear. Higher expression of the vascular cell adhesion molecule 1 (VCAM-1) increases leukocyte-brain endothelium interaction and has been associated with larger infarct size following acute ischemic stroke (AIS). The activation of the TGF-β signaling pathways can down-regulate VCAM-1 expression and ameliorate deleterious tissue outcome during neuroinflammation. Hypothesis: We sought to investigate whether genetic variation in the TGF-beta pathway and adhesion molecule genes is associated with acute stroke lesion size. Methods: We completed genome-wide association (GWA) testing and diffusion-weighted imaging lesion volume (DWIv) analysis in a discovery cohort of 532 AIS patients of European ancestry enrolled within 48 hours of symptom onset. An independent European ancestry cohort of 724 AIS patients with GWA data and automated DWIv served as replication cohort. GWA testing per SNP was performed using linear regression modeling of natural log-transformed DWIv adjusted for age, sex and relevant principal components. We selected 42 inflammatory genes in the TGF-beta pathway for a gene-based analysis using VEGAS (Versatile Gene-based -Association Study) software. A pre-specified discovery phase Bonferroni-corrected threshold was set at p<0.001. In the replication phase, 14 SNPs overlapping were tested at the Bonferroni-corrected p-value threshold of p<0.004. Results: Of all genes in the TGF-beta pathway, VCAM1 (p=0.0006) was significantly associated with DWIv in the discovery AIS cohort (age: 66 ± 14.9 years, sex: 63.4% male, DWIv: 2.2cm 3 (IQR: 0.6-11.7cm 3 )). A single SNP within the VCAM1 gene boundaries (rs3176876 (BETA=0.2341, p=0.003)) was significantly associated with DWIv in the replication AIS cohort (age: 65 ± 14.1 years, sex: 68.6% male, DWIv: 4cm 3 (IQR: 1.3-17.2cm 3 )). Conclusion: The genetic variant rs3176876 in the VCAM1 gene is associated with larger infarct lesion size measured on brain MRI of AIS patients. These findings suggest genetic contribution to the pro-inflammatory mechanisms in acute cerebral ischemia and warrant further investigation.
Abstract TMP58: Determinants of White Matter Hyperintensity in Acute Ischemic Stroke Patients: The MRI-GENIE Study
Sridharan, Ramesh, Cloonan, Lisa, Xu, Huichun , McArdle, Patrick F. , Jiménez-Conde, Jordi , Kleindorfer, Dawn , Schmidt, Reinhold , Sharma, Pankaj , Słowik, Agnieszka , Woo, Daniel , Worrall, Bradford B. , Kittner, Steven J. , Rosand, Jonathan, Golland, Polina , Rost, Natalia S. , Giese, Anne‐Katrin , Schirmer, Markus D. , Dalca, Adrian Vasile , Cole, John W. , Broderick, Joseph P. , Jern, Christina , Kissela, Brett , Lemmens, Robin , Lindgren, Arne G. , Meschia, James F. , Rundek, Tatjana , Sacco, Ralph L. , Thijs, Vincent , Wu, Ona , Mitchell, Braxton D. , Rosand, Jonathan M.

Mayo Clinic

Stroke | June 21, 2021 | Volume: 48 | Issue: suppl_1 | Pages: No page available

10.1161/str.48.suppl_1.tmp58 Get It

Introduction: White matter hyperintensity (WMH) is a highly heritable trait and a significant contributor to stroke risk and severity. Vascular risk factors contribute to WMH severity; however, knowledge of the determinants of WMH in acute ischemic stroke (AIS) is still limited. Hypothesis: WMH volume (WMHv) varies across AIS subtypes and is modified by vascular risk factors. Methods: We extracted WMHv from the clinical MRI scans of 2683 AIS subjects from the MRI-Genetics Interface Exploration (MRI-GENIE) study using a novel fully-automated, volumetric analysis pipeline. Demographic data, stroke risk factors and stroke subtyping for the Causative Classification of Stroke (CCS) were performed at each of the 12 international study sites. WMHv was natural log-transformed for linear regression analyses. Results: Median WMHv was 5.7cm 3 (interquartile range (IQR): 2.2-12.8cm 3 ). In univariable analysis, age (63.1 ± 14.7 years, β=0.04, SE=0.002), prior stroke (10.2%, β=0.66, SE=0.08), hypertension (65.4%, β=0.75, SE=0.05), diabetes mellitus (23.1%, β=0.35, SE=0.06), coronary artery disease (17.6%, β=0.04, SE=0.002), and atrial fibrillation (14.6%, β=0.48, SE=0.07) were significant predictors of WMHv (all p<0.0001), as well as smoking status (52.2%, β=0.15, SE=0.05, p=0.005), race (16.5% Non-Caucasian, β=0.25, SE=0.07) and ethnicity (8.2% Hispanic, β=0.30, SE=0.11) (all p<0.01). In multivariable analysis, age (β=0.04, SE=0.002), prior stroke (β=0.56, SE=0.08), hypertension (β=0.33, SE=0.05), smoking status (β=0.16, SE=0.05), race (β=0.42, SE=0.06), and ethnicity (β=0.34, SE=0.09) were independent predictors of WMHv (all p<0.0001), as well as diabetes mellitus (β=0.13, SE=0.06, p=0.02). WMHv differed significantly (p<0.0001, unadjusted) across CCS stroke subtypes: cardioembolic stroke (8.0cm 3 , IQR: 4.2-15.4cm 3 ), large-artery stroke (6.9cm 3 , IQR: 3.1-14.7cm 3 ), small-vessel stroke (5.8cm 3 , IQR: 2.5-13.5cm 3 ), stroke of undetermined (4.7cm 3 , IQR: 1.6-11.0cm 3 ) or other (2.55cm 3 , IQR: 0.9-8.8cm 3 ) causes. Conclusion: In this largest-to-date, multicenter hospital-based cohort of AIS patients with automated WMHv analysis, common vascular risk factors contribute significantly to WMH burden and WMHv varies by CCS subtype.
Abstract 136: Genetics of White Matter Hyperintensity Burden in Patients With Ischemic Stroke: The MRI-GENIE Study
Xu, Huichun , Dave, Tushar , McArdle, Patrick F. , Jiménez-Conde, Jordi , Kleindorfer, Dawn , Sacco, Ralph L., Schmidt, Reinhold , Sharma, Pankaj , Słowik, Agnieszka , Woo, Daniel , Worrall, Bradford B. , Kittner, Steven J. , Golland, Polina , Rost, Natalia S. , Giese, Anne‐Katrin , Ryan, Kathleen A. , Schirmer, Markus D. , Dalca, Adrian Vasile , Cole, John W. , Broderick, Joseph P. , Jern, Christina , Kissela, Brett , Lemmens, Robin , Lindgren, Arne G. , Meschia, James F. , Rundek, Tatjana , Thijs, Vincent , Wu, Ona , Rosand, Jonathan M. , Mitchell, Braxton D.

Mayo Clinic

Stroke | June 21, 2021 | Volume: 48 | Issue: suppl_1 | Pages: No page available

10.1161/str.48.suppl_1.136 Get It

Introduction: The MRI-Genetics Interface Exploration (MRI-GENIE) study is the first international collaboration that aims to facilitate genetic discoveries in clinical cohorts of patients with acute ischemic stroke (AIS). We have amassed the largest-to-date collection of AIS cases with brain MRI scans and genome-wide genotyping to test the role of genetic susceptibility in MRI-based cerebrovascular traits. Objective/Hypothesis: To elucidate the genetic architecture of white matter hyperintensity (WMH) burden in AIS patients. Methods: Using a novel automated algorithm, we extracted WMH volume (WMHv) from clinical MRI scans of 2704 AIS patients (age 63.1 ± 14.7 years, 60.6% male) of European ancestry. Quality control (QC) measures were undertaken per subject and per SNP, excluding subjects with non-European ancestry and poor genotyping, as well as SNPs deviating from Hardy-Weinberg equilibrium and high levels of missingness. Imputation to the Haplotype Reference Consortium (HRC version r1.1) was conducted for 1712 remaining subjects with 2.8 million SNPs on the Michigan Imputation Server. After exclusion of poorly imputed SNPs (R 2 <0.5) and SNPs with minor allele frequency < 1%, 7.7 million SNPs remained for further analysis. Genome-wide association testing of natural log-transformed WMHv on the allelic dosage per SNP was adjusted for age, sex and principal components 1-10. Results: Genome-wide association testing has identified a novel locus on chromosome 2 (T allele at rs72856504) near the LDL Receptor related Protein 1B gene (LRP1B) that was significantly associated with WMHv burden in AIS (β=0.54, SE=0.098, p=3.65*10 -8 ). Conclusion: We have identified a novel locus (T allele rs72856504) on chromosome 2 near the LRP1B gene, which is specific for WMH in AIS and has not been previosuly described in stroke-free WMH cohorts. A replication effort involving additional independent cohorts of AIS patients with brain MRI and genome-wide genotyping is ongoing.
Age‐related differences in cerebrovascular reactivity in response to COX inhibition
Hines, Casey N., Nicholson, Wayne T. , Katušić, Zvonimir S. , Barnes, Jill N. , Schmidt, John E. , Joyner, Michael J.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.1024.9 Get It

Reduced cerebral blood flow and reactivity may explain age‐related changes in cognitive function. We examined cerebrovascular reactivity, and the potential role of prostaglandins, in young and old healthy humans. Middle cerebral artery velocity (MCAv) responses to stepped hypercapnia were measured in young (26±2y; 6M/5F) and old (66±2y, 3M/4F) adults before (PRE) and 90 min after (POST) oral indomethacin (1.2mg/kg). To account for any changes in blood pressure, cerebrovascular conductance index (CVCi) was calculated as the MCAv divided by mean arterial pressure. Cerebrovascular reactivity slopes were calculated using linear regression between either MCA velocity or CVCi and end‐tidal CO 2 . There were no differences between young and old adults in height, weight, BMI, or brachial blood pressures. Young adults demonstrated greater MCAv (53.7±6.7 vs. 32.0±3.3), MCAv reactivity (1.62±0.21 vs. 0.94±0.10), and CVCi (0.66±0.08 vs. 0.39±0.04) compared with old adults at PRE (P<0.05 for all). In both young and old adults, MCAv, MCAv reactivity, CVCi, and CVCi reactivity decreased between PRE and POST measurements. Furthermore, any age‐related differences in these cerebrovascular variables were abolished by indomethacin. These results suggest that cerebral blood flow and cerebrovascular reactivity is attenuated in aging adults and that this reduction may be mediated by prostaglandins. NIH: AG16574‐11PP2
Announcing the Editorial Board Fellowship Program of the American Journal of Physiology-Lung Cellular and Molecular Physiology
Shimoda, Larissa A. , Bai, Chunxue , Bartlett, Nathan W. , Bastarache, Julie A. , Kuebler, Wolfgang M. , Prakash, Y. S. , Schmidt, Eric P. , Morty, Rory E. , Prakash, Y S , Feghali‐Bostwick, Carol A.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | June 9, 2021 | Volume: 321 | Issue: 1 | Pages: L116-L118

10.1152/ajplung.00239.2021 Get It

First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.
Mody, Kabir , Sahai, Vaibhav , Schmidt‐Kittler, Oleg , Shen, Jinshan , Jen, Kai Yu , Deary, Alicia, Sherwin, Cori Ann , Padval, Mahesh V. , Wolf, Beni B. , Sahai, Vaibhav , Schram, Alison M. , Kamath, Suneel Deepak , El-Khoueiry, Anthony B. , Borad, Mitesh J. , Mahipal, Amit , Goyal, Lipika , Subbiah, Vivek

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: TPS4165-TPS4165

10.1200/jco.2021.39.15_suppl.tps4165 Get It

TPS4165 Background: Oncogenic activation of FGFR2 via genomic rearrangement, gene amplification, or point mutation in advanced solid tumors provides the opportunity for rapid clinical development of highly selective FGFR2 inhibitors using a precision oncology approach to deliver clinical benefit to genomically-defined patient (pt) populations. Unfortunately, this opportunity remains largely unrealized as current, non-selective small molecule inhibitors (pan-FGFRi) suffer from off-isoform toxicity (FGFR1-hyperphosphatemia; FGFR4-diarrhea) and on-target acquired resistance leading to only modest efficacy primarily limited to FGFR2-fusion+ intrahepatic cholangiocarcinoma (ICC). RLY-4008 is a novel, oral FGFR2 inhibitor designed to overcome the limitations of pan-FGFRi by potently and selectively targeting primary oncogenic FGFR2 alterations and acquired resistance mutations. We initiated a first-in-human (FIH) precision oncology study of RLY-4008 in advanced solid tumor pts with FGFR2 alterations with primary objectives to define the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) and adverse event (AE) profile of RLY-4008 and key secondary objectives to assess FGFR2 genotype in blood and tumor tissue, pharmacokinetics (PK), and anti-tumor activity. Methods: This is a global, multi-center, FIH dose escalation/expansion study of RLY-4008 (NCT04526106) in adult pts who have unresectable or metastatic solid tumors with FGFR2 alteration per local assessment, ECOG performance status 0-2, measurable or evaluable disease per RECIST 1.1, and who are refractory, intolerant, or declined standard therapy including pan-FGFRi. FGFR2 alteration will be confirmed retrospectively by central laboratory assessment. For the dose escalation (Ñ50), RLY-4008 is administered QD/BID on a continuous schedule with 4-week cycles according to a Bayesian Optimal Interval design that allows accelerated dose titration, additional accrual to dose levels declared tolerable, and exploration of alternative schedules if warranted. The MTD is determined via logistic regression of the dose limiting toxicity rate across all dose levels and an RP2D less than the MTD may be considered based on observed AEs, PK, and anti-tumor activity. Following dose escalation, the dose expansion (Ñ75) will treat pts with RLY-4008 at the MTD/RP2D and includes 5 groups with any prior therapy (except group 2): 1. FGFR2 fusion+ ICC pts; 2. FGFR2 fusion+ ICC pts with no prior FGFRi; 3. FGFR2 fusion+ pts with other solid tumors; 4. FGFR2-mutation+ solid tumor pts and 5. FGFR2-amplified solid tumor pts. The primary endpoints are MTD/RP2D and AE profile; key secondary endpoints are FGFR2 genotype in blood and tumor tissue, PK parameters; overall response rate, and duration of response per RECIST 1.1. US enrollment began SEP2020 and Europe/Asia start-up is underway. Clinical trial information: NCT04526106.
Evidence that the Functional β-Actin Gene Is Single Copy in Most Mice and Is Associated with 5′ Sequences Capable of Conferring Serum- and Cycloheximide-Dependent Regulation
Elder, Paula K., French, Chris L., Subramaniam, Malayannan , Schmidt, Lucy J., Getz, Michael J.

Mayo Clinic

Molecular and Cellular Biology | May 27, 2021 | Volume: 8 | Issue: 1 | Pages: 480-485

10.1128/mcb.8.1.480-485.1988 | PMID 3422100 Get It

Corticosteroid therapy for COVID-19
Pulakurthi, Yashwitha Sai, Pederson, John M. , Gupta, Nitin , Balasubramanian, Prasanth , Kamrowski, Shelby, Schmidt, Megan , Dibas, Mahmoud , Reierson, Natalie L., Pisipati, Sailaja , Joseph, Betsy Ann, Selvan, Pragadeesh Thamarai , Dmytriw, Adam A. , Keesari, Praneeth Reddy , Sriram, Varsha, Chittajallu, Spandana , Brinjikji, Waleed , Katamreddy, Rewanth R., Chibbar, Richa , Davis, Amber R. , Malpe, Manashree, Mishra, Hemant Kumar , Evanson, Kirk W. , Evanson, Kirk W , Dmytriw, Adam A , Pederson, John M , Dibas, Mahmoud , Gupta, Nitin , Saravu, Kavitha , Vegivinti, Charan Thej Reddy , Mishra, Hemant K., Kallmes, Kevin M , Hassan, Ameer E

Mayo Clinic

Medicine | May 18, 2021 | Volume: 100 | Issue: 20 | Pages: e25719

10.1097/md.0000000000025719 | PMID 34011029 Get It

Abstract Background: Corticosteroid treatment is an effective and common therapeutic strategy for various inflammatory lung pathologies and may be an effective treatment for coronavirus disease 2019 (COVID-19). The purpose of this systematic review and meta-analysis of current literature was to investigate the clinical outcomes associated with corticosteroid treatment of COVID-19. Methods: We systematically searched PubMed, medRxiv, Web of Science, and Scopus databases through March 10, 2021 to identify randomized controlled trials (RCTs) that evaluated the effects of corticosteroid therapies for COVID-19 treatment. Outcomes of interest were mortality, need for mechanical ventilation, serious adverse events (SAEs), and superinfection. Results: A total of 7737 patients from 8 RCTs were included in the quantitative meta-analysis, of which 2795 (36.1%) patients received corticosteroids plus standard of care (SOC) while 4942 (63.9%) patients received placebo and/or SOC alone. The odds of mortality were significantly lower in patients that received corticosteroids as compared to SOC (odds ratio [OR] = 0.85 [95% CI: 0.76; 0.95], P = .003). Corticosteroid treatment reduced the odds of a need for mechanical ventilation as compared to SOC (OR = 0.76 [95% CI: 0.59; 0.97], P = .030). There was no significant difference between the corticosteroid and SOC groups with regards to SAEs and superinfections. Conclusion: Corticosteroid treatment can reduce the odds for mortality and the need for mechanical ventilation in severe COVID-19 patients.
Energy‐integrating‐detector multi‐energy CT: Implementation and a phantom study
Ren, Liqiang , Allmendinger, Thomas , Halaweish, Ahmed F., Schmidt, Bernhard , Flohr, Thomas , Yu, Lifeng , McCollough, Cynthia H. , Yu, Lifeng

Mayo Clinic

Medical Physics | May 14, 2021 | Volume: 48 | Issue: 9 | Pages: 4857-4871

10.1002/mp.14943 | PMID 33988849 Get It

PurposeMulti‐energy computed tomography (MECT) has a great potential to enable many novel clinical applications such as simultaneous multi‐contrast imaging. The purpose of this study was to implement triple‐beam MECT on a traditional energy‐integrating‐detector (EID) CT platform (EID‐MECT).MethodsThis was accomplished by mounting a z‐axis split‐filter (0.05 mm Au, 0.6 mm Sn) on Tube A of a dual‐source EID CT scanner. With the two split x‐ray beams from Tube A and the third beam from Tube B, three beams with different x‐ray spectra can be simultaneously acquired. With Tube B operated at 70 or 80 kV and Tube A at 120 or 140 kV, four different triple‐beam configurations were calibrated for MECT measurements: 70/Au120/Sn120, 80/Au120/Sn120, 70/Au140/Sn140, and 80/Au140/Sn140 kV. Iodine (I), gadolinium (Gd), bismuth (Bi) samples, and their mixtures were prepared for 2 three‐material‐decomposition tasks and 1 four‐material‐decomposition task. For each task, samples were placed in a water phantom and scanned using each of the four triple‐beam configurations. For comparison, the same phantom was also scanned using three other dual‐energy CT (DECT) or MECT technologies: twin‐beam DECT (TB‐DECT), dual‐source DECT (DS‐DECT), and photon‐counting‐detector CT (PCD‐CT), all with optimal x‐ray spectrum settings and at equal volume CT dose index (CTDIvol). The phantom for four‐material decomposition (I/Gd/Bi/Water imaging) was scanned using the PCD‐CT only (140 kV with 25, 50, 75, and 90 keV). Image‐based material decomposition was performed to acquire material‐specific images, on which the mean basis material concentrations and noise levels were measured and compared across all triple‐beam configurations in EID‐MECT and various DECT/MECT systems.ResultsThe optimal triple‐beam configuration was task‐dependent with 70/Au120/Sn120, 70/Au140/Sn140, and 70/Au120/Sn120 kV for I/Gd/Water, I/Bi/Water, and I/Gd/Bi/Water material decomposition tasks, respectively. At equal radiation dose level, EID‐MECT provided comparable or better quantification accuracy in material‐specific images for all three material decomposition tasks, compared to EID‐based DECT and PCD‐CT systems. In terms of noise level comparison, EID‐MECT‐derived material‐specific images showed lower noise levels than TB‐DECT and DS‐DECT, but slightly higher than that from PCD‐CT in I/Gd/Water imaging. For I/Bi/Water imaging, EID‐MECT showed a comparable noise level to DS‐DECT, and a much lower noise level than TB‐DECT and PCD‐CT in all material‐specific images. For the four‐material decomposition task involving I/Gd/Bi/Water, the bismuth‐specific image derived from EID‐MECT was slightly noisier, but both iodine‐ and gadolinium‐specific images showed much lower noise levels in comparison to PCD‐CT.ConclusionsFor the first time, an EID‐based MECT system that can simultaneously acquire three x‐ray spectra measurements was implemented on a clinical scanner, which demonstrated comparable or better imaging performance than existing DECT and MECT systems.
Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?
Park, JooYong , Choi, Ji‐Yeob , Chung, Seokang , Song, Nan , Park, Sue K. , Han, Wonshik , Noh, Dong‐Young , Ahn, Sei-Hyun, Lee, Jong Won, Kim, Mi Kyung , Jee, Sun Ha , Wen, Wanqing , Bolla, Manjeet K. , Wang, Qin , Michailidou, Kyriaki , Shah, Mitul , Conroy, Don, Harrington, Patricia, Mayes, Rebecca , Hall, Per , Patel, Alpa V. , Couch, Fergus J. , Sawyer, Elinor J. , Roylance, Rebecca , Bojesen, Stig E. , Flyger, Henrik, Lambrechts, Diether , Baten, Adinda , Matsuo, Keitaro , Ito, Hidemi , Guénel, Pascal , Keeman, Renske , Schmidt, Marjanka K. , Wu, Anna H. , Tseng, Chiu-Chen, Cox, Angela , Investigators, kConFab, Andrulis, Irene L. , Hopper, John L., Wu, Pei‐Ei , Shen, Chen‐Yang , Fasching, Peter A. , Ekici, Arif B. , Muir, Kenneth, Brenner, Hermann , Arndt, Volker , Jones, Michael E. , Swerdlow, Anthony J, Hoppe, Reiner , Ko, Yon-Dschun, Hartman, Mikael , Li, Jingmei , Mannermaa, Arto, Hartikainen, Jaana M. , Benítez, Javier, Haiman, Christopher A. , Dörk, Thilo , Bogdanova, Natalia , Teo, Soo‐Hwang , Taib, Nur Aishah Mohd , Fletcher, Olivia, Johnson, Nichola , Grip, Mervi, Winqvist, Robert , Nevanlinna, Heli , Lindblom, Annika , Wendt, Camilla, Kristensen, Vessela N. , Collaborators, NBCS, Tollenaar, Rob A.�E.�M. , Heemskerk‐Gerritsen, Bernadette A. M. , Bonanni, Bernardo , Hamann, Ute, Manoochehri, Mehdi, Martinez, Maria Elena, Easton, Douglas F., Yoo, Keun-Young, Lambrechts, Diether , Song, Nan , Park, Sue K , Kim, Mi Kyung , Dennis, Joe , Michailidou, Kyriaki , Hall, Per N , Matsuo, Keitaro , Ito, Hidemi , Keeman, Renske , Schmidt, Marjanka K , Fasching, Peter A , Brenner, Hermann , Arndt, Volker , Hartikainen, Jaana M , Dörk, Thilo , Bogdanova, Natalia V , Johnson, Nichola , Nevanlinna, H , Heemskerk-Gerritsen, Bernadette A M , Bonanni, Bernardo , Lambrechts, Diether , Teo, Soo H , Jones, Michael E , Lambrechts, Diether , Cox, Angela , Guénel, Pascal , Hartman, Mikael , Li, Jingmei , Ekici, Arif B , Bojesen, Stig E , Lindblom, Annika , Mohd Taib, Nur Aishah , Sawyer, Elinor J , Choi, Jaesung , Czene, Kamila , Teras, Lauren R. , Couch, Fergus J. , Olson, Janet E. , Truong, Thérèse , Cross, Simon S. , Investigators, kConFab, Southey, Melissa C. , Lophatananon, Artitaya , Ko, Yon‐Dschun, Mannermaa, Arto , González‐Neira, Anna , Fletcher, Olivia , Blomqvist, Carl , Wendt, Camilla, Collaborators, NBCS, Radice, Paolo , Manoochehri, Mehdi, Lacey, James V. , Dunning, Alison M. , Pharoah, Paul D.P. , Kang, Daehee

Mayo Clinic

Cancers | May 14, 2021 | Volume: 13 | Issue: 10 | Pages: 2370

10.3390/cancers13102370 | PMID 34069208 Get It

In this study we aim to examine gene–environment interactions (GxEs) between genes involved with estrogen metabolism and environmental factors related to estrogen exposure. GxE analyses were conducted with 1970 Korean breast cancer cases and 2052 controls in the case-control study, the Seoul Breast Cancer Study (SEBCS). A total of 11,555 SNPs from the 137 candidate genes were included in the GxE analyses with eight established environmental factors. A replication test was conducted by using an independent population from the Breast Cancer Association Consortium (BCAC), with 62,485 Europeans and 9047 Asians. The GxE tests were performed by using two-step methods in GxEScan software. Two interactions were found in the SEBCS. The first interaction was shown between rs13035764 of NCOA1 and age at menarche in the GE|2df model (p-2df = 1.2 × 10−3). The age at menarche before 14 years old was associated with the high risk of breast cancer, and the risk was higher when subjects had homozygous minor allele G. The second GxE was shown between rs851998 near ESR1 and height in the GE|2df model (p-2df = 1.1 × 10−4). Height taller than 160 cm was associated with a high risk of breast cancer, and the risk increased when the minor allele was added. The findings were not replicated in the BCAC. These results would suggest specificity in Koreans for breast cancer risk.